GlassScriptPhysician profile
Summer B Davies
NPI 1851945356
$3,578.51
in general payments reported to CMS, 2019-2025
29 companies · $748 in 2025
The $748 reported for 2025 was more than what 83% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.53 · 2022: $423 · 2023: $1,127 · 2024: $1,261 · 2025: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,136.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $619.69 | 2022-2025 | Verquvo, Capvaxive, Winrevair |
| Novartis Pharmaceuticals Corporation | $348.60 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $319.29 | 2022-2025 | Sotyktu, Camzyos, Eliquis |
| Inspire Medical Systems, INC. | $289.51 | 2022-2025 | Inspire |
| Janssen Pharmaceuticals, INC | $273.01 | 2022-2024 | Xarelto |
| Pfizer INC. | $263.02 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.98 | 2023-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $229.62 | 2022-2024 | |
| Amgen INC. | $161.42 | 2022-2025 | Repatha, Repatha |
| Daiichi Sankyo INC. | $145.94 | 2024 | Injectafer |
| Novo Nordisk INC | $101.21 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Alnylam Pharmaceuticals INC. | $76.38 | 2024 | Amvuttra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $72.22 | 2022 | |
| Esperion Therapeutics, INC. | $64.44 | 2023-2025 | Nexletol |
| Edwards Lifesciences Corporation | $41.49 | 2022-2023 | Sapien 3 Ultra Resilia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $40.73 | 2024-2025 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals LP | $33.03 | 2023 | Farxiga, Brilinta |
| Baxter Healthcare | $26.92 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Lantheus Medical Imaging, INC. | $25.40 | 2025 | |
| Verona Pharma, INC. | $25.01 | 2025 | Ohtuvayre |
| Tactile Systems Technology INC | $24.04 | 2025 | Nimbl, Flexitouch Plus |
| Kiniksa Pharmaceuticals, LTD. | $23.02 | 2023 | Arcalyst |
| Amarin Pharma, INC. | $22.74 | 2022 | |
| Cvrx, INC. | $22.47 | 2022 | |
| Cardiva Medical, INC. | $19.53 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $18.81 | 2024 | Arcalyst |
| Vivaquant INC, Dba Rhythm Express | $16.68 | 2025 | Rhythm Express |
| Chiesi USA, INC. | $16.05 | 2023 | Kengreal, Cleviprex |
| Heartflow, INC. | $15.26 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Summer Davies listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.